TTI 1612

Drug Profile

TTI 1612

Alternative Names: Soluble HB-EGF like growth factor - Stem Cell Therapeutics; Soluble heparin-binding epidermal growth factor-like growth factor - Stem Cell Therapeutics; TTI-1612

Latest Information Update: 30 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trillium Therapeutics
  • Class Anti-inflammatories; Cytoprotectives; Growth factors; Recombinant proteins; Urologics
  • Mechanism of Action Epidermal growth factor receptor agonists; Epithelial cell stimulants; Intracellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute enterocolitis
  • New Molecular Entity No
  • Available For Licensing Yes - Interstitial cystitis

Highest Development Phases

  • No development reported Interstitial cystitis
  • Discontinued Acute enterocolitis

Most Recent Events

  • 02 Jun 2014 Stem Therapeutics changes its name to Trillium Therapeutics
  • 16 May 2013 TTI 1612 is still available for partnering as of 16 May 2013. www.stemcellthera.com
  • 16 May 2013 Trillium Therapeutics completes dosing in its phase I trial in Interstitial cystitis in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top